Efficacy.
No difference was observed in time to alleviation or improvement of COVID-19 symptoms maintained for 21.5 h between the arms; median time to alleviation or improvement of symptoms was 57.2 h (80% CI, 24.6 to 80.4), 56.4 h (80% CI, 33.9 to 79.0), and 43.4 h (80% CI, 34.3 to 46.3) in the bemnifosbuvir 550 mg, bemnifosbuvir 1,100 mg, and pooled placebo arms, respectively (Fig. S8).